GBS GLUCOSE BIOSENSOR SYS

Intelligent Bio Solutions to Participate in the Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

Intelligent Bio Solutions to Participate in the Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will present at the upcoming Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference on December 3-4, 2024, in Boca Raton, FL.

Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

Dates: December 3-4, 2024

Location: Florida Atlantic University, Boca Raton, FL

Presentation Day and Time: Wednesday, December 4, 2024, at 2:00 p.m. ET  

Presentation Location: Presentation Room 3

A link to the recording of the presentation will be available on INBS’s two days after the event.

Management will also be available during the event for one-on-one meetings with the investment community. To schedule a meeting, please contact your NobleCon representative or KCSA Strategic Communications by emailing .

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.

For more information, visit: 

Company Contact:  

Intelligent Bio Solutions Inc.  

  

Investor & Media Contact:   

Valter Pinto, Managing Director   

KCSA Strategic Communications   

PH: (212) 896-1254   



EN
21/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GLUCOSE BIOSENSOR SYS

 PRESS RELEASE

Intelligent Bio Solutions and Spjotgard Drive Rapid Adoption of Finger...

Intelligent Bio Solutions and Spjotgard Drive Rapid Adoption of Fingerprint Drug Testing Across Scandinavia With over 450 accounts across 24 countries, INBS continues to advance the evolution of drug screening technology NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, non-invasive drug screening solutions, today announced the success of its ongoing partnership with Spjotgard, an established distributor serving the Scandinavian market. The collaboration is acceleratin...

 PRESS RELEASE

Intelligent Bio Solutions Launches In-House Fingerprint Drug Testing A...

Intelligent Bio Solutions Launches In-House Fingerprint Drug Testing Across 20+ Sites for Major Australian Waste Operator, Accelerating APAC Expansion NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Managed Waste Service (“MWS”), a leading Australian waste management provider, plans to implement INBS’ Intelligent Fingerprinting Drug Screening System across its New South Wales operations, including its land cle...

 PRESS RELEASE

Intelligent Bio Solutions Expands U.S. Forensic Market Presence, Seeks...

Intelligent Bio Solutions Expands U.S. Forensic Market Presence, Seeks FDA Clearance for Breakthrough Fingerprint Drug Testing SMARTOX has deployed over 50 of INBS’ Intelligent Fingerprinting Drug Screening Readers and facilitated over 7,000 screening tests, including more than 1,500 tests in 2024 alone Company continues to actively pursue FDA clearance in connection with planned expansion into broader U.S. markets in 2025 NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intel...

 PRESS RELEASE

Intelligent Bio Solutions to Showcase Fingerprint Drug Testing at RISE...

Intelligent Bio Solutions to Showcase Fingerprint Drug Testing at RISE25 Conference from May 28-31, Supporting Innovation in U.S. Forensic Drug Testing INBS to participate with U.S. distribution partner SMARTOX at RISE25, the leading U.S. conference on addiction, mental health, and justice innovation which draws over 7,000 attendees annually With over 450 active accounts across 24 countries, INBS continues to meet growing global demand for reliable, on-site drug testing solutions across the workplace, treatment, and justice sectors NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Intelligent ...

 PRESS RELEASE

Intelligent Bio Solutions Showcases Rapid, Non-Invasive Drug Testing C...

Intelligent Bio Solutions Showcases Rapid, Non-Invasive Drug Testing Capabilities in Remote Queensland Workforce Deployment Completion of 160 tests conducted in less than 90 minutes demonstrates a level of speed and efficiency beyond the limits of traditional testing approaches NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of a high-volume workforce drug test for Barcaldine Regional Cou...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch